Inhalable drugs for systemic therapy

Respiratory Care

Volumn 45, Issue 7, 2000, Pages 831-835

  Corkery, Kevin ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

Aerosol; Inhalable; Macromolecule; Metered dose inhaler; Nebulizer; Peptides; Systemic

Indexed keywords

BRONCHODILATING AGENT; GLUCOCORTICOID;

AEROSOL; CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DELIVERY SYSTEM; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MACROMOLECULE; NEBULIZER; PATHOPHYSIOLOGY; REVIEW;

ADMINISTRATION, INHALATION; AEROSOLS; BRONCHODILATOR AGENTS; DRUG DELIVERY SYSTEMS; GLUCOCORTICOIDS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MACROMOLECULAR SUBSTANCES; NEBULIZERS AND VAPORIZERS;

EID: 0034219389     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Costa B, Estopa A, Borras J, Sabate A. [Diabetes and pharmacoeconomics: efficiency of insulin injection methods available in Spain]. Aten Primaria 1995;16(7):391-396. (article in Spanish)
2. Ilium L, Fischer AN. Intranasal delivery of peptides and proteins. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker; 1997: 135-184.
3. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19:3-36.
4. American Conference of Governmental Industrial Hygienists. Threshold limit values for chemical substances and physical agents and biological exposure indices, 1992-1993. Cincinnati, OH: American Conference of Governmental Industrial Hygienists; 1993: 29.
5. Mackay M, Phillips J. Steward A, Hastewell J. Pulmonary absorption of therapeutic peptides and proteins. In: Byron P, editor. Respiratory Drug Delivery IV conference proceedings. University of Virginia 1994;31-37.
6. Adjeji AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker; 1997.
7. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 1995;12(2-3):151-231.
8. Adjei A, Gupta P. Pulmonary delivery of therapeutic peptides and proteins. J Controlled Release 1994;29:361-373.
9. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994 7(1):49-75.
10. Patton JS, Platz RM. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 1992;8:179-228.
11. Ward JJ, Hess DR, Helmholz HF Jr. Humidity and aerosol therapy. In: Burton JG, Hodgkin JE, Ward JJ. Respiratory care: a guide to clinical practice. 4th ed. Philadelphia: Lippincott; 1997:421-468.
12. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986; 75:433-438.
13. Lalor CB, Hickey AJ. Generation and characterization of aerosols for drug delivery to the lungs. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker; 1997: 235-276.
14. O'Riordan TG, Palmer LB, Smaldone GC. Aerosol deposition in mechanically ventilated patients: optimizing nebulizer delivery. Am J Respir Crit Care Med 1994;149(1):214-219.
15. Patton JS, Platz RM. Aerosol insulin: a brief review. In: Byron P, editor. Respiratory Drug Delivery IV conference proceedings. University of Virginia 1994:65-74.
16. Colthorpe P, FarR SJ, Taylor G,. Smith IJ, Wyalt D. The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm Res 1992;9(6): 764-768.
17. Patton J, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999;35:235-247.
18. Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha l-antitrypsin deficiency directly augmented with an aerosol of alpha l-antitrypsin. Ann Intern Med 1989;111(3):206-212.
19. Patton JS, McCabe JG, Hansen SE, Daugherty AL. Absorption of human growth hormone from the rat lung. Biotechnol Ther 1989-90:1(3):213-228.
20. Colthorpe P, Farr SJ, Sith IJ, Wyatt D, Taylor G. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharm Res 1995;12(3):356-359.
21. Martin RJ, Boguniewicz M, Henson JE, Celniker AC, Williams M, Giorno RC, Leung DYM. The effects of inhaled interferon gamma in normal human airways. Am Rev Respir Dis 1993;148(6 Pt 1):1677-1682.
22. Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivery peptides and proteins: alpha-interferon, calcitonins and parathyroid hormone. J Controlled Release 1994;28:79-85.
23. Niven RW, Whitcomb KL, Shaner L, Ip AY, Kinstler OB. The pulmonary absorption of aerosolized and intratrachealy instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm Res 1995;12(9):1343-1349.
24. Niven RW, Lott, FD, Cribbs JM. Pulmonary absorption of recombinant methionyl human granulocyte colony stimulation factor (r-huG-CSF) after intratracheal instillation to the hamster. Pharm Res 1993;10(11):1604-1610.
25. Niven RW, Lott FD, Ip AY, Cribbs JM. Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit. Pharm Res 1994; 11(8):1101-1109.
26. Adjei AL, Carrigan PJ. Pulmonary bioavailabilily of LH-RH analogs: Some biopharmaceutical guidelines. J Biopharm Sci 1992;3(1-2):247-254.